← FDA DRUG APPROVALS

FDA ANDA · ANDA064155

CEFACLOR

Sponsor: RANBAXY

APPLICATION
ANDA064155
TYPE
ANDA
ORIGINAL APPROVAL
1997-10-02
LATEST ACTION
2001-03-23
ROUTE
ORAL
DOSAGE FORM
FOR SUSPENSION
MARKETING STATUS
Discontinued

Products

CEFACLORDiscontinued
CEFACLOR EQ 375MG BASE/5ML · FOR SUSPENSION · ORAL

Approval history

2001-03-23Manufacturing (CMC) · Supplement 5AP
2000-02-23Labeling · Supplement 4AP
1999-08-30Labeling · Supplement 2AP
1999-04-28Manufacturing (CMC) · Supplement 1AP
1997-10-02OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →